Important Safety Information

Helixate^® FS is a recombinant factor VIII (FVIII) product used to treat hemophilia A when there is a demonstrated deficiency of FVIII, a plasma clotting factor.

Helixate^® FS should be administered cautiously in patients with previous hypersensitivity to constituents of FVIII or known sensitivity to mouse or hamster protein.

Helixate^® FS should not be used by people with von Willebrand disease because it does not contain von Willebrand factor—a different protein associated with a different bleeding disorder. For more information about von Willebrand disease, please visit www.AllAboutBleeding.com.

Adverse events are generally minor. The most common events include injection-site reactions, dizziness, and rash.

For more information about Helixate^® FS, please see the full Prescribing Information.

Helixatefs.com

Important Safety Information for Helixate^®FS

Helixate^® FS is a recombinant factor VIII (FVIII) product used to treat hemophilia A when there is a demonstrated deficiency of FVIII, a plasma clotting factor.

Helixate^® FS should be administered cautiously in patients with previous hypersensitivity to constituents of FVIII preparations of known sensitivity to mouse or hamster protein.

Adverse events are generally minor. The most common adverse events include injection-site reactions, dizziness, and rash.

For more information about Helixate^® FS, please see full Prescribing Information.